PALO ALTO, Calif.– Overture Life, a pioneer in automated in vitro fertilization (IVF) technology, has named Matthew Combs as its new Chief Commercial Officer as the company prepares to scale its fertility automation solutions globally in response to surging demand and critical embryologist shortages.
Combs brings more than 15 years of commercial leadership experience in healthcare and medtech, having previously held key roles at Butterfly Network, Boston Scientific, Stryker, and FUJIFILM Sonosite. At Butterfly Network, he was the first commercial hire and played a central role in scaling the company’s operations to over $70 million in annual revenue, ultimately helping lead it through its public market debut in 2021.
At Overture, Combs will spearhead global commercialization efforts for technologies including the ICSI.A, the world’s first robot for automated fertilization, and DaVitri, a vitrification system that aims to expand egg freezing access beyond specialized IVF centers. These platforms automate intricate steps in the IVF process, previously done by hand, to address labor shortages and improve consistency and efficiency in fertility clinics.
“We’re seeing clinics from the U.S. and Europe to Latin America and Asia asking when they can get our systems,” said Hans Gangeskar, CEO of Overture Life. “Matt’s track record building Butterfly Network into a public company gives us exactly the commercial expertise we need as we move from proving our technology works to scaling it globally. The demand is increasing exponentially as clinics want automation that actually delivers tangible results.”
Combs said Overture’s mission echoes the disruptive momentum he witnessed early in his career. “What I’ve seen with Overture’s technology reminds me of the early excitement around Butterfly Network, that sense of a solution arriving at exactly the right moment,” he said. “IVF has been constrained by manual processes that create barriers to accessibility and inconsistency in performance. Overture’s automation addresses real operational challenges that clinics face every day, from embryologist shortages to the need for affordable and predictable outcomes.”
The company made history by delivering the first live births from fully automated fertilization and egg freezing. With demand for fertility treatment increasing worldwide, Overture is positioning its technology to bring greater accessibility and scalability to IVF procedures, reshaping the future of reproductive care.
